The Color of Stem Cells
By Josef Tayag,
The Greenlining Institute
| 09. 09. 2005
Why the benefits of stem cell research might not be for people like me.
After losing half of one of my lungs to tuberculosis while
volunteering in the Andes last year, I assumed that life would
just never be the same again. By this I meant that the flight
of stairs to my apartment would always seem twice as long and
that I would have to give up things I enjoyed like taking long
runs on Sunday mornings.
However, the promise of therapeutic treatments derived from
stem cell research gives individuals like me a hope for normalcy.
Yet, as an immigrant from a low-income family, I can’t
stop from cringing at the thought that the low-income and marginalized
communities of the state still have no explicit guarantee of
access to the promised 'cures' of Prop. 71—much less to
adequate health care in general.
Last Friday, the Independent Citizen’s Oversight Committee
(ICOC) allocated a little over $39 million to prestigious research
institutions like UCLA, UC Berkeley, Stanford, USC, and Cal
Tech among others. Yet, it’s unclear from perusing through
many of their grant proposals just how much focus these research
institutions will give to communities...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...